The earnings call presented a positive outlook with strong growth in the innovative portfolio and progress in R&D, offset by some challenges in the generics business and uncertainties around external factors like tariffs and IRA negotiations.

Company Guidance -

Q3 2025

During the Q2 2025 earnings call for Teva Pharmaceutical Industries, the company provided optimistic guidance, marking their 10th consecutive quarter of growth. Revenue increased by 1% to $4.2 billion, driven predominantly by their innovative portfolio, with AUSTEDO growing 19% to nearly $500 million, UZEDY increasing 120% to $54 million, and AJOVY up 31% to $155 million. Despite a 2% decline in the Global Generics business and an 11% drop in TAPI, the company expressed confidence in hitting mid-single-digit average growth rates by 2027. The adjusted EBITDA rose by 7%, non-GAAP EPS by 10%, and net debt to EBITDA stood just over 3. Teva reaffirmed its 2025 guidance, projecting revenues between $16.8 billion and $17.2 billion, while expecting its innovative portfolio to over-deliver, raising the combined guidance for AUSTEDO, UZEDY, and AJOVY by $95 million for the year.

10 Consecutive Quarters of Growth

The company has achieved its 10th consecutive quarter of growth, with revenues up to $4.2 billion, marking a 1% increase compared to the previous year.

Strong Performance of Innovative Portfolio

AUSTEDO revenues reached just below $500 million with a 19% increase, UZEDY grew by 120% to $54 million, and AJOVY saw a 31% increase to $155 million.

Improved Financial Metrics

Adjusted EBITDA increased by 7%, non-GAAP EPS rose by 10%, and free cash flow grew by 47% to $476 million.

Progress in R&D Pipeline

The late-stage pipeline is expected to generate over $10 billion in peak sales, and the company is on track with multiple Phase III programs.

Transformation and Cost Savings

The company is on track to deliver $700 million in net savings by 2027, with 20% of the savings already achieved.

Teva (IL:TEVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IL:TEVA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	228.30 / -	257.9	―	―	―
Jul 30, 2025	2025 (Q2)	208.80 / 222.80	229.4	-2.88% (-6.60)	―	―
May 07, 2025	2025 (Q1)	169.90 / 186.50	178.2	4.66% (+8.30)	―	―
Jan 29, 2025	2024 (Q4)	254.40 / 255.40	363.8	-29.80% (-108.40)	―	―
Nov 06, 2024	2024 (Q3)	247.90 / 257.90	230.2	12.03% (+27.70)	―	―
Jul 31, 2024	2024 (Q2)	202.00 / 229.40	205.7	11.52% (+23.70)	―	―
May 08, 2024	2024 (Q1)	192.70 / 178.20	145.9	22.14% (+32.30)	―	―
Jan 31, 2024	2023 (Q4)	285.80 / 363.80	247.7	46.87% (+116.10)	―	―
Nov 08, 2023	2023 (Q3)	238.30 / 230.20	211.2	9.00% (+19.00)	―	―
Aug 02, 2023	2023 (Q2)	193.60 / 205.70	232.7	-11.60% (-27.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IL:TEVA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	5560.00	5690.00	+2.34%
May 07, 2025	6099.00	6150.00	+0.84%
Jan 29, 2025	7960.00	6785.00	-14.76%
Nov 06, 2024	6952.00	6650.00	-4.34%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Teva Pharmaceutical Industries Limited (IL:TEVA) report earnings?

Teva Pharmaceutical Industries Limited (IL:TEVA) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Teva Pharmaceutical Industries Limited (IL:TEVA) earnings time?

Teva Pharmaceutical Industries Limited (IL:TEVA) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Teva Pharmaceutical Industries Limited stock?

The P/E ratio of Teva is N/A.

What is IL:TEVA EPS forecast?

IL:TEVA EPS forecast for the fiscal quarter 2025 (Q3) is 228.3.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing